June 22, 2023 07:39 AM EDTUpdated 02:37 PM
Cell/Gene Tx
FDA+

Sarep­ta's gene ther­a­py for Duchenne ex­pect­ed to get FDA rul­ing to­day

Jaimy Lee

Deputy Editor

Up­date: On Thurs­day af­ter­noon, the FDA grant­ed ac­cel­er­at­ed ap­proval to Sarep­ta’s gene ther­a­py. To read the full sto­ry, click here.

Sarep­ta Ther­a­peu­tics is set …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Stem cell start­up spun out of George Church’s lab rais­es $75M

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

FDA re­jects Van­da’s treat­ment for di­ges­tion con­di­tion, com­pa­ny re­bukes agen­cy's ac­tions

Up­stream Bio files for IPO in sign of life for biotech pub­lic of­fer­ings

Edge­wise’s stock surges as heart drug pass­es ear­ly safe­ty test

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times